Cluster Headaches are accepted to be because of a blend of ecological and hereditary components. Around 66% of cases keep running in families. Changing hormone levels might likewise assume a part, as headaches influence marginally a bigger number of young men than young ladies before pubescence, yet around a few times a larger number of ladies than men.
Mean age at onset of cluster headache was 26.7 ± 10.9 years. Only 13 patients (10.8%) had previously been diagnosed with cluster headache. Mean time to diagnosis from first symptoms was 8.2 ± 7.1 years (range, 0-35 years). Chronic cluster headache was observed in only 9 patients (7.5%). The most commonly reported location of cluster headache was temporal region (75.0%), followed by retro-orbital region (68.3%), forehead (32.5%), vertex (32.5%) and occipital (22.5%).
Cluster duration was 1-2 months in 32.5% of patients. During cluster periods, 73.3% of patients had 1-2 attacks per day, and 39.2% experienced cluster attacks ranging in duration from 1 h to less than 2 h. The duration of attacks were 1.5 (1-2.25) hours for males and 1.5 (1-3) for females respectively. The World Health Organization quality of life-8 questionnaire showed that cluster headache reduced life quality.
Preventive medications: These types of drugs are taken regularly, often on a daily basis, to reduce the severity or frequency of cluster headaches. The FDA is currently reviewing a new migraine drug called Trexima, which combines the migraine drug Imitrex (sumitriptan) and naproxen sodium (a nonsteroidal anti-inflammatory drug) contained in Aleve and other over-the-counter medications.